Medtronic Simplera (standalone)
Medtronic
What it is
Disposable CGM for phone monitoring and the InPen-based MiniMed Go injection system. US use is for adults 18+; the European MiniMed Go announcement includes younger children with conditions. It needs no routine calibration, but the US label requires a meter for treatment decisions in the first 12 hours. Accuracy varies by study and reference method.
Editorial review: .
Most recent recorded citation date: 2026-02-25. Only explicit date metadata is included; an undated citation may be newer. This does not mean every claim was reviewed on that date.
Trial status, labels and access can change between reviews. How we review the evidence · How to read the evidence
Evidence behind this assessment
Key evidence notes. Study results, product eligibility and access answer different questions.
- Who was studied?
- Study populations and analysis groups vary. Product age limits alone do not describe who was studied.
- Benefit or performance
- Accuracy: In a 24-adult comparison, Simplera MARD was 11.6% against venous YSI, equal to Libre 3 and below G7’s 12.0%. It was higher than both with the other tested reference methods; capillary MARD during frequent sampling was 16.6%.[3]
- Important harms and treatment burden
- Read the safety discussion and original sources. A missing summary does not establish safety.
- Approval and country access
- US manufacturer start pathway and a dated gradual European launch are documented. Country-specific stock, funding and younger-age eligibility need local confirmation.Approval, trial recruitment, local supply and funding are separate. Check the cited label or access source.
- Follow-up and remaining uncertainty
- Read the full discussion and original sources for follow-up duration and study limitations.
This record cites company or conference reports. Those sources may describe interim findings; their source type is shown in the source list.
Editorial score: calculation and evidence
A weighted editorial judgment on a 0–100 scale, not a probability of success or a measured treatment effect. Higher criterion scores mean more favorable assessments.
Score limitations. Scores are retained editorial assessments, not calibrated probabilities or a pooled comparison of devices. Study methods, reference instruments and populations differ; regional access is only partly checked.
Default calculation: 60 × 20 + 55 × 15 + 30 × 15 + 60 × 10 + 88 × 10 + 75 × 10 + 82 × 10 + 0 × 5 + 55 × 5 = 5800; divide by total weight 100. Unrounded weighted result: 58.
In a 24-adult comparison, Simplera MARD was 11.6% against venous YSI, equal to Libre 3 and below G7’s 12.0%. It was higher than both with the other tested reference methods; capillary MARD during frequent sampling was 16.6%.[3]
During glucose rises above 2 mg/dL/min, the head-to-head study reported 20.1% MARD and −19.9% bias for Simplera from 229 YSI pairs. These are accuracy and bias measures, not a directly measured delay in minutes.[3]
The US comparison page lists Simplera for InPen and the separate Simplera Sync for 780G. This assesses the documented manufacturer configurations; it does not establish compatibility with every other or open-source system.[8]
The US label specifies up to six days followed by a 24-hour grace period. In its clinical performance section, estimated survival was 75.2% through day 6 and 66.7% through day 7, from 128 sensors with 11 censored.[1]
No routine calibration is required and optional calibration is available. US users must use a blood glucose meter for treatment decisions during the first 12 hours and when readings do not match symptoms or sensor data are unavailable.[1]
The US app supports adjustable high/low alerts, an alert before low up to 60 minutes ahead, and a urgent-low alert at 63 mg/dL or below. Receiving phone or watch alerts depends on compatible devices, connection and notification settings.[1]
A disposable all-in-one sensor worn on the upper arm, without a separate reusable transmitter. The current US Smart MDI page says no overtape is required.[9]
The current US Smart MDI page offers an InPen-with-Simplera start pathway and says components are sold separately. This establishes an advertised route, not stock availability or insurance approval for a particular person.[9]
The full picture
Simplera is a disposable glucose sensor with a phone app and an InPen connection for people using insulin injections. It is distinct from Simplera Sync, which is listed for the MiniMed 780G pump. The two names do not identify interchangeable configurations.89
Who can use it. The FDA approved standalone Simplera on 24 July 2024, for adults 18 years and older; 7 August was the company’s announcement date. The 25 February 2026 European MiniMed Go announcement describes use from age 7, and ages 2–6 with adult caregiver supervision. That regional statement does not extend the US age label.27
Accuracy in the US label. The clinical performance study enrolled 123 adults with type 1 or type 2 diabetes; 118 completed. The overall accuracy table contains 116 participants and 15,405 paired sensor–YSI readings, giving a MARD of 10.2%. Raw sensor signals were processed retrospectively with the final algorithm. MARD is an average relative error measure; it is not the percentage of readings that are accurate or a guarantee for an individual reading.1
Head-to-head evidence. In 24 adults with type 1 diabetes wearing three systems simultaneously, Simplera’s venous YSI MARD was 11.6% from 1,932 pairs, the same as Libre 3’s 11.6% and slightly below G7’s 12.0%. Simplera had higher MARD with the other reference methods: 13.9% against Cobas and 16.6% against capillary Contour Next during frequent sampling. Thus the study does not show Simplera worse against every reference. Its first 12-hour capillary MARD was 20.0%. The study received no funding from the tested CGM manufacturers, but disclosed other industry support and author relationships.3
Exercise and flight studies. A 20-adult laboratory/home study found overall Simplera median absolute relative difference 13.8% from 719 capillary-reference pairs, versus 8.4% for G7 and 7.5% for Libre 3; this combined exercise-laboratory and home periods. A separate 20-person flight pilot reported Simplera overall mean participant MARD 19.9%, using 18 participants and 744 pairs across flight and ground periods. Its in-flight value was 26.4% in 17 participants/363 pairs. These small studies used different settings and summaries; their percentages should not be pooled. The exercise study had Abbott, Ascensia and Dexcom material support; the flight study reported EASA/ÖDG funding and Insulet travel support.45
Wear and fingersticks. The US guide specifies six days plus a 24-hour grace period and a two-hour warm-up. Routine calibration is unnecessary, but a meter must guide treatment during the first 12 hours, and when symptoms disagree with readings or sensor data are unavailable. Optional calibration does not remove those instructions. The label’s sensor-survival analysis estimated 66.7% through day 7; a different 24-person comparison estimated 81.5% through seven days from 49 Simplera sensors, with a 95% confidence interval of 67.5–89.9%. Different protocols and censoring prevent treating these as one failure rate.13
Alerts and water. The US app offers adjustable high/low alerts, an alert before low up to 60 minutes ahead and a urgent-low alert at 63 mg/dL or below. Apple Watch display depends on a paired compatible phone and appropriate settings. The worn sensor’s water limit is 2.4 metres for up to 30 minutes. It measures glucose, not ketones.1
Important safety limits. The US guide warns against CGM use with hydroxyurea and warns that acetaminophen/paracetamol can falsely raise readings. It also addresses skin reactions, insertion-site infection and exposure to MRI or other strong magnetic fields. A lot-specific recall concerned Simplera model MMT-5100JD1, lot HG81GLZ, because a cap-label defect could compromise sterility. FDA lists distribution in six European countries and no US distribution; this is not a recall of every Simplera sensor. Follow the linked notice’s affected-lot instructions.110
Access as checked 17 September 2026. The US Smart MDI page offers a start pathway for InPen with Simplera, and the current MiniMed Go page includes Simplera while foregrounding Instinct in its offer. The European February announcement described a gradual launch. These sources establish specific commercial pathways, not supply in every European country or universal reimbursement. Local stock and individual funding were not confirmed in this review.967
Sources
- [1]Simplera system user guide — US · Manufacturer — US instructions: adults 18+, first 12-hour meter requirement, six days plus 24-hour grace, optional calibration, interference and water limits. Clinical performance Table 4: 116 participants and 15,405 SG–YSI pairs; retrospective final algorithm. Read 17 September 2026.
- [2]FDA Simplera approval overview — P160007/S047 · Regulatory decision · 2024-07-24 — Decision date 24 July 2024; the company announcement on 7 August is a different date. US age 18+ and meter/interference exceptions.
- [3]Performance of Three Continuous Glucose Monitoring Systems in Adults With Type 1 Diabetes · Peer-reviewed study · 2025-02-04 — Full original, Tables 3–5 and Figure 5: 24 adults, with comparator-specific results. No funding from the three tested CGM manufacturers; other industry funding and author relationships disclosed.
- [4]Performance of three simultaneously used rtCGM systems around a physically active weekend camp in adults with type 1 diabetes: A prospective lab and real-world study · Peer-reviewed study · 2025-12-19 — Full original, Table 2: 20 adults; overall Simplera median ARD 13.8% from 719 capillary-reference pairs, combining laboratory and home periods. Material support from Abbott, Ascensia and Dexcom; author relationships disclosed. Online 19 December 2025, 2026 journal issue.
- [5]Performance of continuous glucose monitoring systems during commercial flights in T1DM: A within-subject comparative pilot study · Peer-reviewed study · 2026-01-02 — Full original, Table 1: 20 participants enrolled; Simplera analysis 18 participants/744 pairs overall. Mean participant MARD 19.9% includes flight and ground; in-flight 26.4% in 17 participants/363 pairs. EASA/ÖDG funding, Insulet travel support and author relationships disclosed.
- [6]MiniMed Go — current US compatibility · Manufacturer — Current US product page includes Simplera and Instinct; Simplera age 18+. Its offer foregrounds Instinct. Product compatibility does not prove individual coverage or immediate stock. Read 17 September 2026.
- [7]European commercial rollout of MiniMed Go with Simplera · Manufacturer · 2026-02-25 — Dated launch announcement: gradual European rollout from February 2026; ages 7+, or 2–6 with adult supervision. Not a country-by-country stock or funding list.
- [8]Medtronic continuous glucose monitors — US comparison · Manufacturer — Separates Simplera/InPen from Simplera Sync/780G and Guardian 4/780G. Current product configuration and wear information; no clinical superiority inference. Read 17 September 2026.
- [9]US Smart MDI system — InPen with Simplera · Manufacturer — Current US get-started pathway; components sold separately; disposable sensor and no overtape. Actual fulfilment and individual coverage not tested. Read 17 September 2026.
- [10]FDA recall Z-0033-2026 — specified Simplera lot · Regulatory decision · 2025-10-02 — Initiated 7 May 2025, posted 2 October 2025. Model MMT-5100JD1, lot HG81GLZ; cap-label adhesion/sterility concern. Distribution Austria, Belgium, Italy, Spain, Switzerland and UK; no US distribution. Open/classified when read 17 September 2026.